# 1 Title

2 Safety and efficacy of two immunization schedules with an inactivated SARS-

**3** CoV-2 vaccine in adults. A randomized non-inferiority clinical trial.

4 Authors

Katia Abarca<sup>1,2\*</sup>. Carolina Iturriaga<sup>1</sup>. Marcela Urzúa<sup>1,3</sup>. Nicole Le Corre<sup>1</sup>. Augusto 5 Pineda<sup>1,4</sup>, Carolina Fernández<sup>1</sup>, Angélica Domínguez<sup>5</sup>, Pablo A González<sup>2,6</sup>, Susan M 6 Bueno<sup>2,6</sup>, Paulina Donato<sup>7</sup>, Pilar Espinoza<sup>8</sup>, Daniela Fuentes<sup>9</sup>, Marcela González<sup>10</sup>, 7 Paula Guzmán<sup>11</sup>, Paula Muñoz<sup>12</sup>, Carlos M Pérez<sup>8</sup>, Marcela Potin<sup>1,13</sup>, Álvaro Rojas<sup>3</sup>, 8 José V González-Aramundiz<sup>14</sup>, Nicolás MS Gálvez<sup>2</sup>, Francisca Aguirre-Boza<sup>11,12</sup>, Sofía 9 Aliaro<sup>15</sup>, Luis Federico Bátiz<sup>12,13</sup>, Yessica Campisto<sup>7</sup>, Marcela Cepeda<sup>9</sup>, Aarón Cortes<sup>11</sup>, 10 Sofía López<sup>15</sup>, María Loreto Pérez<sup>8</sup>, Andrea Schilling<sup>14</sup>, CoronaVac03CL Study Group, 11 and Alexis M Kalergis<sup>2,6,15</sup>\*. 12

### 13 Affiliations

<sup>1</sup>Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División de

15 Pediatría, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

<sup>2</sup>Millennium Institute on Immunology and Immunotherapy.

<sup>17</sup> <sup>3</sup>Departamento de Enfermedades Infecciosas del adulto, División de Medicina Interna,

18 School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

<sup>4</sup>Medicina Física y Rehabilitación, Red de Salud UC Christus, Santiago, Chile
 <sup>5</sup>Departamento de Salud Pública, School of Medicine, Pontificia Universidad Católica
 Chile, Santiago, Chile.

- <sup>6</sup>Millennium Institute on Immunology and Immunotherapy. Departamento de Genética
- 23 Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad
- 24 Católica de Chile, Santiago, Chile.
- <sup>7</sup>Complejo Asistencial Dr. Sótero del Río, Santiago, Chile.
- <sup>8</sup>Hospital Félix Bulnes, Facultad de Medicina y Ciencia y Facultad de Ciencias para el
- 27 Cuidado de la Salud, Universidad San Sebastián, Santiago, Chile.
- <sup>9</sup>Hospital Carlos Van Buren, Universidad de Valparaíso, V Región, Chile.
- <sup>10</sup>Hospital Gustavo Fricke, Universidad de Valparaíso, V Región, Chile.
- <sup>11</sup>Clínica Universidad de Los Andes, Universidad de Los Andes, Santiago, Chile.
- <sup>12</sup> Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago, Chile.
- <sup>13</sup>Clínica San Carlos de Apoquindo, Red de Salud UC, Santiago, Chile.
- 33 <sup>14</sup>Departamento de Farmacia, Facultad de Química y de Farmacia, Pontificia
- 34 Universidad Católica de Chile, Santiago, Chile.
- 35 <sup>15</sup>Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina,
- 36 Pontificia Universidad Católica de Chile, Santiago, Chile.

### 37 Keywords:

CoronaVac<sup>®</sup>; Phase 3 clinical trial; SARS-CoV-2; COVID-19; Vaccines; immunization
 schedules.

Short running title: CoronaVac<sup>®</sup> safety and efficacy in adults by two immunization
schedules.

42 **\*Corresponding authors**: Katia Abarca (kabarca@uc.cl/+56996797787) and Alexis M.

Kalergis (akalergis@bio.puc.cl/+56223541924); Av. Libertador Bernardo O'Higgins
#340, Santiago, Chile.

## 45 Research in context

### 46 Evidence before this study

47 CoronaVac<sup>®</sup> (an inactivated SARS-CoV-2 vaccine) was approved on June 1<sup>st</sup>, 2021, by 48 the WHO for its use in humans. Sinovac Life Sciences generated this vaccine in China 49 and conducted phase 1/2 trials. Good safety, efficacy, and immunogenicity profiles were 50 reported. The results from this study led to the use of CoronaVac<sup>®</sup> in other countries, 51 such as Brazil, Turkey, and Chile, with phase 3 trials being held on them.

#### 52 Added-value of this study

This work compares the safety and efficacy of two immunization schedules with 53 CoronaVac®, with each dose administrated two or four weeks after the first dose on 54 healthy Chilean adults. To date, no studies showing the safety and efficacy of these two 55 immunization schedules with CoronaVac<sup>®</sup> in healthy adults in a population other than 56 the Chinese have been published. We show that CoronaVac<sup>®</sup> is safe and prevents 57 hospitalization due to COVID-19 in both immunization schedules. No differences were 58 59 found in the incidence of adverse events between both schedules, and no related severe adverse events were reported. These results give further insight into the immune 60 response induced by CoronaVac<sup>®</sup> and are relevant when deciding on the immunization 61 62 schedule chosen for vaccination.

#### 63 Implications of all the available evidence

The data reported here show that using either immunization schedule with two doses of CoronaVac<sup>®</sup> protects against SARS-CoV-2. The data also indicate that CoronaVac<sup>®</sup> does not induce severe adverse events in either immunization schedule, and the adverse events registered are mild and transient, confirming the safety of this vaccine.

## 68 Abstract

Background: Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac<sup>®</sup> (Sinovac Life Sciences), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity in previous studies, preventing severe COVID-19 cases. We further investigated the safety and efficacy of two immunization schedules of CoronaVac<sup>®</sup> in a non-inferiority trial in healthy adults.

**Methods***:* This is a multi-center and randomized clinical trial. Healthy adults were enrolled at eight centers in Chile. Participants were randomly assigned to two vaccination schedules, receiving two doses with either 14 (0-14) or 28 (0-28) days between each. 2302 participants were vaccinated. The primary safety and efficacy endpoints were solicited adverse events (AE) within 7 days after each dose and compared the number of cases of SARS-CoV-2 infection 14 days after the second dose between schedules, respectively.

Findings: The most frequent local AE was pain at the injection site, which was less 81 82 frequent in participants aged ≥60 years. Other local AEs were reported in less than 5% of participants. The most frequent systemic AEs were headache, fatigue, and myalgia. 83 The remaining AEs were minor allergic reactions and fever. Most AEs were mild and 84 transient. There were no significant differences for local and systemic AE between 85 schedules. No anaphylactic reactions or vaccine-related severe AEs were observed. 58 86 87 COVID-19 cases were confirmed, and all but two of them were mild. No differences were observed in protection between schedules. 88

Interpretation: CoronaVac<sup>®</sup> is safe, especially in ≥60 years-old participants. Both
schedules protected against COVID-19 hospitalizations.

# 91 Funding: MINSAL, Chile, CPC & IMII, Chile.

### 92 Background

In March 2020, the COVID-19 pandemic, a disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared <sup>1</sup>. Two years into this pandemic, more than 250 million cases have been diagnosed worldwide, and more than 5 million deaths can be related to COVID-19 <sup>2</sup>. In Chile, since March 2020, 1.7 million laboratory-confirmed cases have been reported, and more than 38,000 deaths can be related to COVID-19 by December 2021 <sup>3</sup>.

Initial COVID-19 outbreaks exhibited high morbidity and mortality in individuals over 60 years of age or with comorbidities, such as obesity, chronic pulmonary disease, cardiac disease, and immunosuppressed population <sup>4,5</sup>. Antiviral drugs or immunomodulators have not been a successful treatment <sup>6</sup>. Prophylactic strategies with drugs, such as hydroxychloroquine or ivermectin did not show any significant reduction in the risk of SARS-CoV-2 infection <sup>7</sup>. Other treatments, such as post-exposure type I interferon prophylaxis, are still being evaluated <sup>8</sup>.

106 Vaccination is an essential prophylactic strategy to prevent pathogen spreading and the disease caused by a viral infection <sup>9</sup>. Early during the pandemic, the development of 107 108 vaccines against SARS-CoV-2 was vigorously pursued. Different vaccine platforms were generated to prevent COVID-19, such as mRNA vaccines or viral vector-based 109 vaccines <sup>10</sup>. Among these, CoronaVac<sup>®</sup> is an inactivated vaccine against SARS-CoV-2 110 developed in Vero cells (Sinovac Life Sciences, Beijing, China). Preclinical studies 111 112 performed in mice, rats, and non-human primates demonstrated that this vaccine was immunogenic and induced anti-SARS-CoV-2 neutralizing antibodies <sup>11</sup>. Moreover, 113 114 partial or complete protection against pneumonia after a viral challenge was shown in

medRxiv preprint doi: https://doi.org/10.1101/2022.02.07.22270215; this version posted March 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

primates <sup>11</sup>. All these results led to human clinical trials. A phase I/II sequential clinical 115 trial was performed, including 144 and 600 healthy adults aged 18 to 59 years, 116 respectively <sup>12</sup>. Two doses (3 and 6 µg) and two vaccination schedules (two doses 117 118 separated by either two or four weeks) were evaluated. Results demonstrated that this inactivated vaccine was well tolerated with mild local adverse events after two doses <sup>12</sup>. 119 120 Although anti-SARS-CoV-2 neutralizing antibodies geometric mean titers (GMT) were 121 lower when compared to convalescent patients, the vaccine induced a significant humoral response with both doses and schedules. A phase1/2 sequential clinical trial 122 performed in healthy adults aged 60 years and older showed that CoronaVac<sup>®</sup> was safe 123 and well-tolerated in this particular population <sup>13</sup>. Moreover, the 3 µg dose in the elderly 124 125 group induced anti-SARS-CoV-2 neutralizing antibodies titers similar to those observed in adults aged 18-59 years. All these findings led to the emergency use of CoronaVac<sup>®</sup> 126 127 in China and supported the development of a phase 3 study to evaluate the efficacy of this inactivated vaccine <sup>14</sup>. 128

Due to the availability of CoronaVac<sup>®</sup> to the general public in Chile since January 2021, we adapted the initial placebo-controlled phase 3 clinical trial in adults to a noninferiority clinical trial of two different immunization schedules, with the second dose administered either two (0-14) or four (0-28) weeks after the first one, with a planned 12 months of follow-up. This report includes the safety and efficacy of non-inferiority results acquired up to six months after the first dose.

### 135 Methods

### 136 Study design and participants

This trial (clinicaltrials.gov NCT04651790) is a multi-center, randomized clinical trial to 137 evaluate two vaccination schedules of CoronaVac<sup>®</sup>, the Sinovac inactivated SARS-138 CoV-2 vaccine, in adults in Chile that included health care workers and community 139 140 participants recruited at eight sites (six in the Metropolitan Region of Santiago and two 141 in the Valparaiso Region). The study was approved by the sponsoring institution Ethical Committee (Comité Ético Científico Ciencias de la Salud UC, Pontificia Universidad 142 143 Católica de Chile, ID 200708006), and each Institutional Ethical Committee of the other sites (Comité Ético Científico Universidad de Los Andes, Comité Ético Científico 144 145 Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Comité Ético Científico Hospital Clínico Félix Bulnes, Comité Ético Científico Servicio de Salud 146 Valparaíso-San Antonio, Comité Ético Científico Servicio de Salud Metropolitano Sur 147 Oriente, Chile), and the Public Health Institute of Chile (ISP Chile, number Nº 148 149 24204/20). This study was also conducted according to the current Tripartite Guidelines for Good Clinical Practices, the Declaration of Helsinki<sup>15</sup>, and local regulations. An 150 151 independent data and safety monitoring board reviewed the blinded safety and efficacy 152 data.

Written informed consent was obtained from each participant before enrollment. After inclusion and exclusion criteria were met (a complete list of inclusion and exclusion criteria has been published previously <sup>16</sup>), participants were randomly assigned to one of 2 open-label vaccination schedules, with either 14 (0-14) or 28 (0-28) days interval between doses, in a 1:1 ratio.

### 158 **Aims**

The primary safety endpoint was to evaluate the frequency of AE occurring on the first 7 days after each dose of the vaccine in each vaccination schedule. The secondary endpoint was to determine the occurrence of SAE and events of special interest in both vaccination schedules during all the study.

The primary non-inferiority efficacy endpoint was to evaluate and compare the protection against confirmed SARS-CoV-2 infection of two vaccination schedules, starting two weeks after the second dose. Non-inferiority of 0-14 over 0-28 schedule was defined as a difference in the protection rate within a threshold of 15%. Secondary efficacy endpoints were to compare both vaccination schedules regarding hospitalized cases and deaths within the same period.

169

### 170 **Procedures**

Demographic information, comorbidities, concomitant medications, and nutritional status 171 172 were registered at enrolment and registered in a paper case report form (CRF) and an 173 electronic CRF (eCRF). Blood samples and nasopharyngeal swabs were obtained for all participants prior to immunization to evaluate past or current SARS-CoV-2 infection. 174 175 A urine test was performed on all female participants to assess potential pregnancies, an exclusion criterion. Participants were inoculated with 3  $\mu$ g (600SU) of Coronavac<sup>®</sup> 176 177 and then kept in observation for 60 min after each dose to evaluate possible adverse events (AE). Immediate AE was defined as reporting the AE within this period. Then, 178 participants, or their representative, if applicable, were instructed to register through a 179 180 remote application any local and systemic solicited AE for 7 days after each dose and

medRxiv preprint doi: https://doi.org/10.1101/2022.02.07.22270215; this version posted March 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

181 any other AE and concomitant medications until 28 days after the second dose. Non-182 immediate AEs were defined as those occurring after the first 60 minutes after vaccination. Serious adverse events (SAE), events of special interest (using the priority 183 List of Events of Special Interest in COVID-19 vaccines by Brighton Collaboration)<sup>17</sup>, 184 relevant medications (immunosuppressive drugs, transfusions, and other vaccines), and 185 186 symptoms of SARS-CoV-2 infection were collected throughout the entire study. The 187 system sent daily reminders to all participants until day 28 after the second dose and 188 then weekly until the end of the study. The severity of solicited AE was graded through a numeric scale of 1 to 4, based on the "Toxicity Grading Scale for Healthy Adult and 189 Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" guide of the Food 190 and Drug Administration of the United States (FDA)<sup>18</sup>. The severity of the unsolicited 191 clinical AE was classified through a numeric scale of 1 to 5, based on the "Common 192 Terminology Criteria for Adverse Events - Version 5.0" guide by the United States 193 National Cancer Institute (NCI /NIH)<sup>19</sup>. The investigators determined a possible causal 194 195 association between AE and vaccination according to a classification adapted from the "Uppsala Monitoring Center" of the World Health Organization<sup>20</sup>. Personnel of the sites 196 197 reviewed this information for accuracy and completeness and filled an AE or SAE form 198 in the eCRF.

To determine the protection against confirmed SARS-CoV-2 infection for each vaccination schedule, participants were followed during the study to identify and register any SARS-CoV-2 infection (COVID-19). The definition of case surveillance for COVID-19 was stated by the WHO <sup>21</sup>. Participants were instructed to register in the remote application and notify the sites through the mail, message, or phone call when they

204 presented at least one of the symptoms for two days (suspicious case definition met). In 205 these cases, a SARS-CoV-2 RT-qPCR was performed. A second sample was collected 206 in the case of a negative RT-gPCR with persisting symptoms, and then a new RT-gPCR 207 was performed. The investigators closely monitored participants who met the confirmed 208 COVID-19 case definition (at least one symptom and a positive RT-qPCR), recording 209 symptoms, severity, start and end dates, therapies, complications, hospitalizations, and 210 admission to the ICU, use of mechanical ventilation, and outcome. The severity of the 211 COVID19 symptoms was classified in 1 to 4 grades based on the guidelines "Toxicity 212 Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials" from the United States Food and Drug Administration (FDA) and 213 214 the "Common Terminology Criteria for Adverse Events - Version 5.0" guide by the United States National Cancer Institute (NCI /NIH) <sup>18,19</sup>. The intensity of the condition 215 216 was registered using the scale of clinical progression (Score 0 to 10), based on the WHO guidelines <sup>20</sup>. 217

218

#### 219 Statistical analyses

Baseline characteristics of patients were compared by schedule: categorical variables were expressed as counts and percentages while numerical variables with mean and standard deviation (SD). Categorical variables were analyzed with Chi-square test or Fisher's exact test; differences in means were tested using Student's t-test; significance level was set at a more rigorous level of 0.01. The percentage of subjects that presented each solicited AE within the first 7 days was obtained for each schedule. The length of the event was presented as median and quantiles 10 and 90. Incidence of

medRxiv preprint doi: https://doi.org/10.1101/2022.02.07.22270215; this version posted March 28, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

227 immediate and non-immediate AE was registered. The number of simultaneous non-228 immediate AEs were expressed as the sum of different AE and are shown as frequency 229 and percentage by dose and schedule. Differences in the incidence of each AE by age 230 were evaluated using Chi-square or Fisher's exact test. The COVID-19 incidence, 231 including only cases occurring 14 days after the second dose, was determined for each 232 schedule and subgroups defined by sociodemographic or clinical characteristics. 233 COVID-19-free survival was estimated using Kaplan-Meier analysis, and schedule 234 curve differences were assessed using the Log Rank test. Cox's regression was used to 235 obtain age and gender-adjusted incidence rate ratios and their 95% confidence interval 236 (CI). The proportional hazards assumption was met. For safety and efficacy, we looked 237 at the non-inferiority of the 0-14 schedule over the 0-28 schedule, with a margin of 15%. 238 Consequently, one-sided statistical tests were used where the rejection of the null 239 hypothesis indicates non-inferiority of the 0-14 schedule over the 0-28 schedule. All 240 statistical analyses were performed using SPSS 17.0.

241

242 Role of the funding source

The funder had no role in study design, data collection, analysis, interpretation, or reportwriting.

## 246 **Results**

#### 247 **Demographics and participants**

During November 29th, 2020, and April 9th, 2021, a total of 2,302 participants were 248 vaccinated with the first dose of CoronaVac®. Of these participants, 1,090 were 249 250 allocated to the 0-14 schedule and 1,212 to the 0-28 schedule. Safety and efficacy data 251 derived from participants up to October 2021 are reported here, with a median (minmax) of follow-up of 6.5 (0.5-6.7) months for the 0-14 schedule and 6.9 (1.1-7.1) months 252 for the 0-28 schedule. Safety information for 7 days after the first and second doses was 253 254 available for 2,302 and 2,212 participants, respectively. These data were included in the 255 safety analysis. Moreover, 2,205 participants had clinical information 14 days after the 256 second dose and were included in the efficacy analysis (Figure 1).

Demographic characteristics and comorbidities of the population are shown in Table 1. No significant differences were observed between participants who received any of the two vaccination schedules, except a higher proportion of health workers in the 0-14 schedule; and a higher BMI and frequency of participants aged over 60 in the 0-28 schedule.

262

### 263 Safety parameters

During the first 60 minutes after vaccination, 1-2% of participants reported local pain at the administration site. The other AEs were recorded in even lower frequency (Supplementary Table 1). No anaphylactic reactions were observed. After this immediate period, a total of 882 local and 1,919 systemic solicited AEs were reported upon administration of the first dose. These AEs were reported in 32.1% and 41.5% of the vaccinated participants for the 0-14 and 0-28 schedules. A total of 867 local and 1395 systemic solicited AE were reported after the second dose. These AEs were reported in 31.2% and 32.9% of the vaccinated participants for the 0-14 and 0-28 schedules, respectively (Figure 1 and supplementary table 2). The 0-14 schedule showed no inferiority to the 0-28 schedule (p<0.0001) in the frequency of AEs (Supplementary Table 2).

275 After the first dose, 67.9% of the participants did not report any local AE, 26.6% 276 reported only pain at the inoculation site, 0.9% reported pain and induration, 0.8% 277 reported pain and local pruritus, and 0.6% reported only pruritus. All other combinations were found in less than 0.5% of the participants. After the second dose, 68.8% of the 278 279 participants did not report any AE, 24.7% reported only pain at the inoculation site, 1.4% 280 reported pain and induration, 0.8% reported pain, induration, and pruritus. All other 281 combinations were found in less than 0.6% of the participants. Majority of the 282 participants who presented any local AE after each dose reported one or two AEs 283 (Supplementary Table 3).

After each dose, the most frequent solicited systemic AEs were headache, fatigue, and 284 285 myalgia, reported in 20-26%, 12-17%, and 11-14% of the participants, respectively. The 286 remaining systemic AEs were reported in less than 10% of the vaccinated participants. 287 Notably, minor allergic reactions and fever were reported by less than 2% and 1% of the 288 vaccinated participants, respectively (Figure 2 and Supplementary Table 2). The 289 number of simultaneous systemic AEs is shown in Supplementary Table 3. The majority of the participants who presented any systemic AE reported one or two simultaneous 290 291 AE. Most local and systemic AEs were mild, with 0.5% or fewer participants reporting

grade 3 AEs after the first dose and 0.6% or less after the second dose. There were no reports of grade 4 AEs (Figure 2). The most frequent local and systemic AEs resolved in a median of 2 days (Supplementary Table 4). When comparing by age group, older participants (≥60 years old) showed less incidence of AEs than did younger participants (18-59 years old) (Supplementary Table 5).

No vaccine-related SAE occurred, and 60 non-vaccine-related SAEs were reported, 297 298 including 3 deaths: two sudden deaths, one due to acute myocardial infarction, one 299 month after the second dose (male, between 50 and 60 years old), and other in a 300 patient with a history of hepatic cirrhosis due to alcoholic liver disease, three months after the second dose (male between 60 and 70 years-old). The third death was due to 301 302 gastric cancer Stage IV diagnosed five months after enrolment (female, between 70 and 303 80 years old). Five pregnancies have been reported in participants of the study, two of 304 them during the first four weeks after the second dose, one twin and one single 305 pregnancy. All had a negative pregnancy test and contraceptive use before each 306 vaccine dose, and these participants are being followed-up by the investigators, with no obstetric nor perinatal complications reported to date. To date, one of the pregnancies 307 308 concluded with the birth of healthy twins. No other events of special interest have 309 occurred in the study.

310

#### 311 Vaccine efficacy

Upon 14 days after the administration of the second dose of CoronaVac<sup>®</sup>, 58 symptomatic and confirmed COVID-19 cases have been registered. The demographic and clinical characteristics of these COVID-19 cases are shown in Table 2. The vast

315 majority of these cases were mild (Score 2) (94.8%), and just two participants were 316 hospitalized. The first one was a male, aged over 60 years, BMI 28.0 (over-weighted), 317 with arterial hypertension and bicuspid aorta. This participant exhibited COVID-19 318 symptoms 32 days after the second dose of a 0-28 schedule and was a confirmed close 319 contact with a COVID-19 case. The participant developed atrial fibrillation and heart failure and required mechanical ventilation (Score 7) for six days and hospitalization for 320 321 20 days. The second participant is a male, aged over 60 years, BMI of 29.3 (over-322 weighted), in treatment for hypothyroidism. The second participant exhibited COVID-19 symptoms 122 days after the second dose of a 0-28 schedule, and no close contact 323 324 with other COVID-19 cases. The participant received oxygen by nasal cannula (Score 325 5) for four days and was released after seven days of hospitalization. Both participants 326 exhibited cough, dyspnea, and fatigue for more than seven weeks but ultimately 327 recovered.

328 A total of 34 and 24 cases of COVID-19 were registered in the 0-14 and the 0-28 329 schedule, respectively (p=0.083) (Table 2). Both schedules showed a high probability of 330 being COVID-19-free: 96.7% (0-14) and 97.9% (0-28) (non-inferiority p-value < 0.001). A Kaplan-Meier analysis showed that the probability of 0.98 for being COVID-19-free is 331 332 achieved at day 91 for the 0-14 schedule and at day 133 for the 0-28 schedule. 333 Although the COVID-19 incidence rate showed a slightly higher curve for the 0-14 than 334 the 0-28 schedule, this difference was not statistically significant (log-rank test, p-value 335 = 0.071) (Figure 3). The 0-14 schedule showed non inferiority to the 0-28 schedule when comparing COVID-19 incidence in different subpopulations defined 336 bv 337 demographic and clinical characteristics (Supplementary Table 6).

The incidence of COVID-19 cases tends to be higher in health care workers compared with the general population for both immunization schedules (for 0-14 schedule, cases presented in 4.5 v/s 2.4% and for 0-28 in 3.1 v/s 1.7%); but these differences were not statistically significant. Also, the infection rate tends to be lower in  $\geq$ 60 years old participants, but the significance level set for this analysis was not achieved (p=0.024). No statistical differences were observed in the frequency of COVID-19 cases between sex and comorbidities.

### 345 Discussion

This non-inferiority trial demonstrated that the virus inactivated, CoronaVac<sup>®</sup>, given in two doses, with a 14 or 28 days interval between each dose, was safe, well-tolerated, and protective. A six-month surveillance showed a non-inferiority of the 0-14 over the 0-28 schedule in solicited AEs and confirmed COVID-19 cases. These results further support the safety and protective capacity for massive use of the Coronavac<sup>®</sup> vaccine in adults, including participants older than 60 years old.

Regarding the safety of CoronaVac<sup>®</sup>, no vaccine-associated SAEs nor events of special 352 interest were reported up until six months of follow-up in this cohort of over 2,300 adults. 353 During phase III trials with adenovirus and mRNA-based vaccine formulations, four and 354 one SAEs were associated with each vaccine, respectively <sup>22,23</sup>. However, post-355 approval reports showed an increased incidence of vaccine-induced thrombotic 356 thrombocytopenia, particularly for the adenovirus-based vaccine prototypes 23 357 Moreover, cases of vaccine-related myocarditis were observed in adolescents and 358 young adults vaccinated with mRNA-based vaccine <sup>24</sup>. 359

CoronaVac<sup>®</sup> showed a low reactogenicity profile, with around 30% of vaccinated 360 participants reporting local pain, less than 1% fever, and no significant allergic 361 reactions. In this line, AEs reported on the phase III trials with CoronaVac<sup>®</sup> performed in 362 Turkey and Brazil were primarily mild and self-limited <sup>25,26</sup>. The low reactogenicity profile 363 of CoronaVac<sup>®</sup> contrasts with the relatively high incidence of local and systemic AEs 364 reported post-vaccination for other vaccine platforms, such as mRNA and adenoviral 365 vectors, with pain observed in 50-80%, fever in 16-51%, fatigue up to 70%, and 366 myalgias up to 60% of the participants <sup>22,27</sup>. 367

Regarding the vulnerable population, 30% of the enrolled participants in this study were 368 ≥60 years old, and 45% had chronic conditions. Lower frequencies of post-vaccination 369 AEs were observed for the older age cohort compared to the younger participants. 370 371 Consistently with this notion, only one elderly subject developed a fever after 372 vaccination, a condition that could escalate in older people. Concordantly, in a nationwide cross-sectional study for side effects of CoronaVac<sup>®</sup> performed in Turkey, 373 374 younger age was a risk factor associated with an discrete increase of vaccine side effects <sup>26</sup>. These features contribute to the confidence for the massive administration of 375 376 this vaccine, especially in the most vulnerable populations.

Although the study design does not allow calculation of true efficacy for the vaccine due 377 378 to the absence of a placebo arm, we demonstrate that in a scenario of high viral circulation<sup>3</sup>, the vast majority of COVID-19 cases developed by vaccinated participants 379 380 were only mild. Only two participants aged over 60 years required hospitalizations, and no deaths due to COVID-19 occurred as part of the study <sup>28</sup>. These data are consistent 381 with the immunogenicity results reported in Chile so far, showing that CoronaVac® 382 383 induces the secretion of specific IgG against the S1-RBD with neutralizing capacity, as well as the activation of T cells specific for SARS-CoV-2 antigens <sup>16</sup>. Moreover, the wide 384 385 use of this vaccine in the Chilean population was monitored by de Ministry of Health 386 and has shown an effectiveness of 67,7% to prevent symptomatic COVID-19 cases and more than 85% to prevent severe COVID-19 cases and deaths due to SARS-CoV-2 387 infection <sup>29</sup>. 388

Comparing the protective efficacy of two different vaccination schedules (0-14 v/s 0-28)
 against SARS-CoV-2 infection could help health authorities make evidence-based

391 decisions for massive immunization against COVID-19. A more rapid schedule could 392 lead to faster vaccination of the population, which could be relevant during an epidemic. It is essential to evaluate differences regarding immunogenicity, efficacy, and 393 394 effectiveness between an accelerated schedule versus a standard four-week interval. Two previous reports with this vaccine showed a more robust immune response for the 395 0-28 schedule than for the 0-14 schedule <sup>12</sup>. A phase I/II trial held in China showed 396 397 higher neutralizing antibodies seroconversion rates for the 0-28 schedule compared to the 0-14 schedule <sup>12</sup>. 398

Regarding efficacy, although we observed a trend toward higher efficacy for the 0-28 399 schedule compared to the 0-14 schedule, these differences were not statistically 400 significant. A previous study that evaluated the efficacy of CoronaVac® in a 0-14 401 402 schedule demonstrated that this parameter was higher in participants who received the two doses with an interval of over 21 days <sup>25</sup>. An explanation for this apparent 403 discrepancy is that in our study, the group included in the 0-14 schedule consisted 404 405 mainly of healthcare workers, which are usually more exposed to the virus and therefore 406 have higher risks of infection. Further studies with a more homogeneous population could contribute to addressing these questions. 407

Older age is a described risk factor related to COVID-19 severity <sup>30</sup>, also observed in our study. Here, the two severe cases reported occurred just in older participants. However, the frequency of cases tended to be lower in this age group. This could be related to the most strict protective measures taken in this population and their lower mobility during the time of the study.

413 After a six-month follow-up, two doses of CoronaVac<sup>®</sup> demonstrated to be well-414 tolerated, safe, and protective, particularly in a high-risk population. Regarding 415 vaccination schedules, our data suggest that both a 0-14 and a 0-28 schedule show 416 equivalent safety and efficacy results for this vaccine.

### 417 **Funding:**

418 The Ministry of Health, Government of Chile, supported the funding of the 419 CoronaVac03CL Study: The Confederation of Production and Commerce (CPC), Chile, 420 supported the funding of the CoronaVac03CL Study; The Millennium Institute on Immunology and Immunotherapy, ANID - Millennium Science Initiative Program 421 ICN09\_016 (former P09/016-F) supports SMB, KA, PAG, and AMK; The Innovation 422 423 Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0) supports SMB, PAG, 424 and AMK. SINOVAC contributed to this study with the investigational vaccine and 425 placebo, and experimental reagents.

426

#### 427 **Declaration of interest:**

428 All authors declare no conflict of interest.

- 429
- 430 Author contributions:
- 431 Conceptualization: KA, PAG, SMB, JVG, AMK,
- 432 **Methodology**: KA, CI, MU, AP, CF, PD, PE, DF, MG, PG, PM, CMP, MP, AR.
- 433 **Investigation**: KA, CI, MU, AP, CF, PD, PE, DF, MG, PG, PM, CMP, MP, AR.
- 434 **Funding acquisition**: SMB, AMK.
- 435 **Project administration**: KA, PAG, SMB, AMK.
- 436 **Supervision**: KA, PAG, SMB, AMK.
- 437 Writing original draft: KA, CI, MU, NLC, AD.
- 438 Writing review & editing: KA, SMB, PAG, NMSG, AMK.

### 440 Acknowledgments

441 We would like to thank the Ministry of Health, Government of Chile; Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile: and The Ministry of 442 443 Foreign Affairs, Government of Chile and the Chilean Public Health Institute (ISP). We also thank the Vice Presidency of Research (VRI), the Direction of Technology Transfer 444 and Development (DTD), the Legal Affairs Department (DAJ) of the Pontificia 445 Universidad Católica de Chile. We are also grateful to the Administrative Directions of 446 447 the School of Biological Sciences and the School of Medicine of the Pontificia 448 Universidad Católica de Chile for their administrative support. Special thanks to the independent data safety monitoring committee (members in the Supplementary 449 450 Appendix (SA)) for their oversight and to the participants enrolled in the study for their 451 participation and commitment to this trial. Members of the CoronaVac03CL Study Team are listed in the SA. 452

453

#### 454 **Data and materials availability:**

455 All analyzed and raw data (masked to protect the information of volunteers) is available 456 upon reasonable request to the corresponding authors through email after the 457 publication of this article. A signed data access agreement will be requested to share 458 the data. The study protocol is also available online and annexed to this article.

#### 459 **References**

- 460 1 Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. *Acta Biomed*461 2020; **91**: 157–60.
- 462 2 WHO. Weekly Epidemiological Update on COVID-19. World Heal Organ 2020; :
- 463 1;4.
- 464 3 Ministerio de Salud G de C. Informe Epidemiológico Nº164 Enfermedad por
- 465 SARS-CoV-2. 2021. https://www.minsal.cl/wp-content/uploads/2021/12/Informe-466 Epidemiológico-164.pdf (accessed Jan 31, 2022).
- 467 4 Booth A, Reed AB, Ponzo S, *et al.* Population risk factors for severe disease and
  468 mortality in COVID-19: A global systematic review and meta-analysis. *PLoS One*469 2021; **16**: e0247461.
- 470 5 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult
- 471 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*472 (*London, England*) 2020; **395**: 1054–62.
- 473 6 Vijayvargiya P, Esquer Garrigos Z, Castillo Almeida NE, Gurram PR, Stevens
- 474 RW, Razonable RR. Treatment Considerations for COVID-19: A Critical Review
- 475 of the Evidence (or Lack Thereof). *Mayo Clin Proc* 2020; **95**: 1454–66.
- 476 7 Bartoszko JJ, Siemieniuk RAC, Kum E, *et al.* Prophylaxis against covid-19: living
  477 systematic review and network meta-analysis. *BMJ* 2021; **373**: n949.
- 478 8 Lee AC, Jeong Y, Lee S, *et al.* Nasopharyngeal Type-I Interferon for Immediately
- 479 Available Prophylaxis Against Emerging Respiratory Viral Infections. *Front*
- 480 *Immunol* 2021; **12**: 660298.
- 481 9 Rodrigues CMC, Plotkin SA. Impact of Vaccines; Health, Economic and Social

- 482 Perspectives. *Front Microbiol* 2020; **11**: 1526.
- 483 10 Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-
- 484 CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. *NPJ*
- 485 *vaccines* 2021; **6**: 28.
- 486 11 Gao Q, Bao L, Mao H, *et al.* Development of an inactivated vaccine candidate for
  487 SARS-CoV-2. *Science* 2020; **369**: 77–81.
- 488 12 Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an
- 489 inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a
- 490 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet
- 491 *Infect Dis* 2021; **21**: 181–92.
- 492 13 Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated
- 493 SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a
- 494 randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet*
- 495 *Infect Dis* 2021; **21**: 803–12.
- 496 14 Staff R. Sinovac's coronavirus vaccine candidate approved for emergency use in
- 497 China –source. 2020. https://www.reuters.com/article/us-health-coronavirus-
- 498 china-vaccines-idUSKBN25O0Z3 (accessed Jan 31, 2022).
- 499 15 Valdespino Gómez JL, García García MDL. Declaración de Helsinki. Gac. Med.
  500 Mex. 2001; **137**: 391.
- 501 16 Bueno SM, Abarca K, González PA, *et al.* Safety and Immunogenicity of an
- 502 Inactivated SARS-CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. *Clin*
- 503 Infect Dis 2021; : 2021.03.31.21254494.
- 504 17 VACcines SP for E. D2.3 Priority List of Adverse Events of Special Interest:

- 505 COVID-19. 2020 https://brightoncollaboration.us/wp-
- 506 content/uploads/2020/06/SPEAC\_D2.3\_V2.0\_COVID-19\_20200525\_public.pdf
- 507 (accessed Jan 31, 2022).
- 508 18 U. S. Department of Health and Human Services, Services USD of H and H,
- 509 Administration F and D, Research C for BE and. Toxicity Grading Scale for
- 510 Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical
- 511 Trials. *Guid Ind* 2007. http://www.fda.gov/cber/guidelines.htm. (accessed Aug 14, 2019).
- 513 19 National Cancer Institute. Common Terminology Criteria for Adverse Events (
  514 CTCAE ) version 5.0. *NIH Publ* 2017.
- 515 20 WHO-UM. The use of the WHO-UMC system for standardized case causality 516 assessment. Uppsala Uppsala Monit. Cent. 2014.
- 517 21 WHO. Public Health Surveillance for COVID-19. Interim Guid 2020; : 253–78.
- 518 22 Polack FP, Thomas SJ, Kitchin N, *et al.* Safety and Efficacy of the BNT162b2
- 519 mRNA Covid-19 Vaccine. *N Engl J Med* 2020; **383**: 2603–15.
- 520 23 Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1
- 521 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four
- 522 randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021.
- 523 DOI:10.1016/S0140-6736(20)32661-1.
- 524 24 Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-
- 525 19 Vaccine in a Nationwide Setting. *N Engl J Med* 2021; **385**: 1078–90.
- 526 25 Palacios R, Batista AP, Albuquerque CSN, et al. Efficacy and Safety of a COVID-
- 527 19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV

528 Study. SSRN Electron J 2021. DOI:10.2139/ssrn.3822780.

- 529 26 Tanriover MD, Doğanay HL, Akova M, et al. Efficacy and safety of an inactivated
- 530 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,
- randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398: 213-
- 532 22.
- 533 27 Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a
- recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,
- open-label, non-randomised, first-in-human trial. *Lancet (London, England)* 2020;
- **395**: 1845–54.
- 537 28 Duarte LF, Gálvez NMS, Iturriaga C, et al. Immune Profile and Clinical Outcome
- 538 of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2
- 539 Vaccine. *Front Immunol* 2021; **12**: 742914.
- 540 29 Jara A, Undurraga EA, González C, *et al.* Effectiveness of an Inactivated SARS-
- 541 CoV-2 Vaccine in Chile. *N Engl J Med* 2021; **385**: 875–84.
- 542 30 Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with COVID-
- 543 19 mortality in the absence of other risk factors? General population cohort study
- of 470,034 participants. *PLoS One* 2020; **15**: e0241824.
- 545
- 546

548	Figure 1. Study design for this Phase 3 trial with two different immunization
549	schedules as of October 2021. This study aims to characterize the safety and efficacy
550	elicited by two immunization schedules with $\textsc{CoronaVac}^{\texttt{®}}$ , with each dose separated by
551	either 14 or 28 days.
552	
553	Figure 2. Frequency and severity of local and systemic adverse events by
554	schedule and dose. Frequencies and severity grades are shown in percentage. (A)
555	Local adverse events. (B & C) Systemic adverse events.
556	
557	Figure 3. Cumulative incidence of COVID-19 infection by immunization schedule.
558	Cumulative incidence for COVID-19 infections 14 days after administration of the
559	second dose in two vaccination schedules (0-14 [solid line] and 0-28 [dashed line]). The
560	X-axis shows days elapsed from the second dose to the event or censoring time.
561	Censoring was set at the date of the third vaccination, retirement from the study, or
562	reaching six months after the second dose, whichever occurred first.
563	

# 564 **Table 1.** Clinic and demographic characteristics of the study population at baseline.

	Total	Schedule 0- 14	Schedule 0- 28	p value
	(n=2302)	(n=1090)	(n=1212)	(a)
Age; n (%)				0.001
18-59	1616	900 (72 4)	916 (67.2)	
60-98	(70.2) 686 (29.8)	800 (73.4) 290 (26.6)	816 (67.3) 396 (32.7)	
Sex; n (%)	000 (29.0)	290 (20.0)	390 (32.7)	0.015
Female	1212 (52.6)	603 (55.3)	609 (50.2)	0.013
BMI; mean ± SD	(0-10) 26.9 ± 4.5	$26.6 \pm 4.4$	$27.1 \pm 4.6$	0.003
Ethnicity; n (%)				0.128
Hispanic or Latino	2294 (99.7)	1083 (99.4)	1211 (99.9)	
Chilean native	4 (0.2)	3 (0.3)	1 (0.1)	
Asian	3 (0.1)	3 (0.3)	0 (0.0)	
Black	1 (0.0)	1 (0.1)	0 (0.0)	
Health workers; n (%)				<0.001
Yes	759 (33.0)	459 (42.1)	300 (24.8)	
Comorbidities; n (%)				
≥1	1042 (45.3)	487 (44.7)	555 (45.8)	0.580
Comorbidities; n (%)				
Cardiovascular disease	34 (1.5)	14 (1.3)	20 (1.7)	0.468
Asthma and COPD*	148 (6.4)	83 (7.6)	65 (5.4)	0.028
Diabetes	117 (5.1)	44 (4.0)	73 (6.0)	0.030
Insulin resistance	180 (7.8)	85 (7.8)	95 (7.8)	0.967
Hypothyroidism	248 (10.8)	135 (12.4)	113 (9.3)	0.018
Arterial hypertension	415 (18.0)	174 (16.0)	241 (19.9)	0.015
Allergic rhinitis	300 (13.0)	137 (12.6)	163 (13.4)	0.531
Thyroid disease	251 (10.9)	136 (12.5)	115 (9.5)	0.022
Obesity	478 (20.8)	205 (18.8)	273 (22.5)	0.028
Dyslipidaemia	43 (1.9)	18 (1.7)	25 (2.1)	0.467


565


	Total	Schedule 0-14	Schedule 0-28
	(n=58)	(n=34)	(n=24)
Age in years, n (%)			-
18-59	48 (82.8)	29 (85.3)	19 (79.2)
60-98	10 (17.2)	5 (14.7)	5 (20.8)
Sex, n (%)			
Female	31 (53.4)	18 (52.9)	13 (54.2)
Clinical score, n (%)			
2 (symptomatic, independent)	55 (94.8)	33 (97.1)	22 (91.7)
3 (symptomatic, assistance needed)	1 (1.7)	0 (0.0)	1 (4.1)
5 (hospitalized, oxygen by mask or nasal prongs)	1 (1.7)	1 (2.9)	0 (0.0)
7 (intubation and mechanical ventilation)	1 (1.7)	0 (0.0)	1 (4.1)
Severity criteria, n (%)			
Hospitalizations	2 (3.4)	1 (2.9)	1 (4.1)
UCI admissions	1 (1.7)	0 (0.0)	1 (4.1)
Deaths	0 (0.0)	0 (0.0)	0 (0.0)
Health setting workers, n (%)			
Yes	28 (48.3)	19 (55.9)	9 (37.5)
Comorbidities, n (%)			
≥1	26 (44.8)	14 (41.2)	12 (50.0)
Comorbidities, n (%)			
Cardiovascular disease	4 (6.9)	2 (5.9)	2 (8.3)
Asthma and COPD*	6 (10.3)	3 (8.8)	3 (12.5)
Diabetes	3 (5.2)	2 (5.9)	1 (4.2)
Insulin resistance	5 (8.6)	1 (2.9)	4 (16.7)
Arterial hypertension	14 (24.1)	9 (26.5)	5 (20.8)
Allergic rhinitis	7 (12.1)	3 (8.8)	4 (16.7)
Thyroid disease	3 (5.2)	3 (8.8)	0 (0.0)
Obesity	14 (24.1)	5 (14.7)	9 (37.5)
Dyslipidaemia	0 (0.0)	0 (0.0)	0 (0.0)

567	Table 2. Characteristics of CO	ID-19 positive participa	nts by immunization schedule.
-----	--------------------------------	--------------------------	-------------------------------

\* COPD: chronic obstructive pulmonary disease

Data are presented as frequency and percentage of the total number of cases in each subgroup and were compared with Chi-square test or Fisher exact test; all p values were higher than 0.05.





■ G1 = G2 = G3 ■ G4

